Sunday, 27 November 2022

News & Events

27 November 2021

New study finds no clear benefit from a shorter optimised vancomycin treatment in babies with Gram positive late onset sepsis


NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the findings of the largest neonatal vancomycin efficacy trial ever conducted: • No clear benefit was seen with the use of an optimised short (5±1 day) course…
12 November 2020

Dr Louise Hill presents sub-study findings at ESPID 2020

Candida and Vancomycin Resistant Enterococcus Colonisation in Septic Neonates on Vancomycin Treatment Neonates are colonised rapidly within the first few hours of life. Antibiotic exposure can disrupt the normal pattern of colonisation, leading to…
7 September 2020

NeoVanc trial in the final stretch towards completion!

The second trial in neonatal sepsis sponsored by Penta is now in its final stretch towards completion. This trial is part of the NeoVanc project, which aimed to analyze the adaptability of an off-label medicine, vancomycin, to the specific needs of…
14 February 2019

Pivotal achievement of 200 participants enrolled in the study!

We are pleased to celebrate the milestone achievement of the randomisation of 200 participants in the NeoVanc project. Congratulations to all the NeoVanc team! A special mention needs to be made on the great effort of investigators, co-investigators…
10 December 2018

7th General Assembly & 4th Investigators Meeting

On 18th and 19th December 2018 the 7th General Assembly and 4th Investigators meeting of NeoVanc project will take place in Athens, Greece. Hosted by PENTA partner CLEO (, the gathering will chiefly focus on consolidating the…
4 September 2018

Over 50% of patients now enrolled!

We are delighted to bring you the news that successful randomisation of over 50% of NeoVanc’s target has been achieved. Congratulations to all the NeoVanc team on hitting this momentous milestone and for your on-going hard work and commitment to the…
20 February 2018

We reached 103 randomised patients!

We are thrilled to congratulate all the NeoVanc Investigators and Co-Investigators for having reached (and exceeded) the important milestone of 100 children enrolled! The effort they have put so far in the NeoVanc project has been essential in…
13 December 2017

The 3rd Investigators Meeting will take place in Barcelona - Spain on 13th December 2017

The program and information about the venue and logistics will be available soon. We look forward to meeting you in Barcelona!
19 September 2017

Patient No. 50 has been enrolled into the study.

We are proud to announce that our milestone of 50 patients has been reached. Congratulations to all recruiting sites for this remarkable result!
24 May 2017

The 2nd Investigators Meeting took place in Madrid on 24th May 2017

The meeting was a success. Many thanks to all participants for their active contribution.


Reserved Access to the our services for our Partners.

Copyright © NeoVanc | All rights reserved. Read the disclaimer.
This project has received funding from the European Union’s Seventh Framework Programme for research, technological development and demonstration under grant agreement no: 602041
Privacy policy | Terms and conditions